Document is current
Any future updates will be listed below
-
Authors
King, John A.
Nichols, Anna-Louise
Bentley, Sian
Carr, Siobhan B.
Davies, Jane C.
- License Information
-
More Information
Article History
Accepted: 6 April 2022
First Online: 16 May 2022
Declarations
:
: No sources of funding were received for the preparation of this article.
: JK, ALN and SB have no conflicts of interest to declare. SBC has performed clinical trial leadership roles, educational and/ or advisory activities for the following: Chiesi, Pharmaxis, Profile Pharma, Vertex Pharmaceuticals and UK CF Trust. JCD has performed clinical trial leadership roles, educational and/or advisory activities for the following: Abbvie, Algipharma AS, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Eloxx, Enterprise, Galapagos NV, ImevaX GmbH, Ionis, Nivalis Therapeutics, Inc., Novartis, ProQR Therapeutics III B.V., Proteostasis Therapeutics, Inc., Pulmocide Raptor Pharmaceuticals, Inc. and Vertex Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: JK is the lead author for the article, whilst all other authors contributed equally to the design, content and review process.
